Table 1.
Top 4 marketed pharmacotherapy products for prostatic therapies 2009
| Annual worldwide sales $US (million) | Group share (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Rank | Product | Generic name | Company | 2007 | 2008 | 2009 | 2007 | 2008 | 2009 |
| 1 | Flomax/Alna/Harnal | Tamsulosin HCl | Boehringer Ingelheim / Astellas Pharma | 2171 | 2279 | 2692 | 48 | 48 | 50 |
| 2 | Avodart/Avolve | Dutasteride | GlaxoSmithKline | 571 | 739 | 830 | 14 | 17 | 17 |
| 3 | Xatral/Uroxatral | Alfuzosin HCl | Sanofi-Aventis | 457 | 486 | 413 | 11 | 11 | 9 |
| 4 | Proscar | Finasteride | Merck & Co | 411 | 324 | 291 | 10 | 8 | 6 |
| Other | 424 | 486 | 554 | 11 | 11 | 12 | |||
| Total | 4033 | 4313 | 4779 | 100 | 100 | 100 | |||
Source: EvaluatePharma® (http://www.evaluatepharma.com).